within Pharmacolibrary.Drugs.ATC.L;

model L01EC03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.855,
    Cl             = 0.00023666666666666665,
    adminDuration  = 600,
    adminMass      = 450 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.164,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007166666666666667,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.517,
    k12             = 50.1,
    k21             = 50.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EC03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Encorafenib is a small molecule BRAF inhibitor used for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, often in combination with binimetinib. It is an approved targeted therapy by the FDA and EMA and inhibits tumor cell proliferation by blocking the MAPK pathway.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with advanced solid tumors (majority male and female adults, median age ~60) after single oral administration of encorafenib.</p><h4>References</h4><ol><li><p>Piscitelli, J, et al., &amp; Williams, JH (2024). Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration. <i>Clinical pharmacokinetics</i> 63(4) 483–496. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01352-9\">10.1007/s40262-024-01352-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38424308/\">https://pubmed.ncbi.nlm.nih.gov/38424308</a></p></li><li><p>Piscitelli, J, et al., &amp; Williams, JH (2024). Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 94(3) 337–347. DOI:<a href=\"https://doi.org/10.1007/s00280-024-04676-2\">10.1007/s00280-024-04676-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38878209/\">https://pubmed.ncbi.nlm.nih.gov/38878209</a></p></li><li><p>Wang, J, et al., &amp; Schinkel, AH (2018). P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. <i>Pharmacological research</i> 129 414–423. DOI:<a href=\"https://doi.org/10.1016/j.phrs.2017.11.006\">10.1016/j.phrs.2017.11.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29155017/\">https://pubmed.ncbi.nlm.nih.gov/29155017</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EC03;
